New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
10:25 EDTBSX, BSX, LLY, LLY, LH, LH, GEVA, GEVA, ACT, ACT, Q, Q, BIO, BIO, HSIC, HSIC, ALOG, ALOG, SIAL, SIAL, WMGI, WMGI, AGIO, AGIO, OPHT, OPHTJPMorgan to host a conference
32nd Annual Healthcare Conference is being held in San Francisco on January 13-16 with webcasted company presentations to begin on January 13 at 10:30 am; not all presentations may be webcasted. Webcast Link
News For OPHT;AGIO;WMGI;SIAL;ALOG;HSIC;BIO;Q;ACT;GEVA;LH;LLY;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 16, 2014
08:02 EDTACTIronwood announces initiation of Phase II linaclotide trial
Ironwood Pharmaceuticals (IRWD) announced the initiation of a Phase II clinical trial evaluating linaclotide for the treatment of adults suffering from opioid-induced constipation. Data are expected in the second half of 2015. The clinical trial is being conducted jointly by Ironwood and Actavis plc (ACT), Ironwood’s co-development and co-promotion partner for linaclotide in the United States. Linaclotide is a guanylate cyclase-C agonist approved by the FDA for the treatment of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation. Linaclotide is not currently approved for the treatment of OIC. The randomized, double-blind, placebo-controlled, multi-site Phase II clinical trial is expected to enroll approximately 240 adult patients with chronic, non-cancer pain who have been receiving a stable dose of an opioid analgesic and suffer from constipation, defined as fewer than three spontaneous bowel movements per week. Patients will be randomized to receive 145 mcg of linaclotide, 290 mcg of linaclotide, or placebo for eight weeks. The primary endpoint of the trial is an increase in SBM frequency. Additionally, a number of secondary endpoints and exploratory analyses intended to inform future development plans are included in the study design.
07:53 EDTGEVASynageva initiated with a Buy at SunTrust
Target $117.
07:23 EDTOPHTIBF Conferences to hold a summit
Ophthalmology Innovation Summit is being held in Chicago on October 16.
October 15, 2014
19:16 EDTLHLabCorp acquisition of LipoScience clears antitrust approval
Laboratory Corporation of America Holdings, or LabCorp (LH), announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the acquisition of LipoScience, Inc. (LPDX) by LabCorp. The transaction is expected to close in Q4.
16:11 EDTLHLabCorp's LipoScience acquisition clears antitrust approval
LipoScience (LPDX) announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the acquisition of LipoScience by Laboratory Corporation of America Holdings (LH). The transaction remains subject to other customary closing conditions set forth in the Agreement and Plan of Merger, dated September 24. The transaction is expected to close in Q4.
07:40 EDTAGIOAgios Pharmaceuticals initiates four expansion cohorts in AG-221 Phase 1 study
Subscribe for More Information
October 14, 2014
07:46 EDTACTActavis should be able to mitigate Irish tax downside, says Leerink
Subscribe for More Information
07:15 EDTLLYBiotech Industry Organization to hold a summit
Subscribe for More Information
06:03 EDTACTMarket overreacted to new Irish tax rules, says BMO Capital
BMO Capital believes the market may have overreacted yesterday to the report that Ireland is eliminating the "Double Irish" tax loophole. The firm says Allergan (AGN) confirmed that it incorporated potential changes to Irish tax law in its recently raised earnings guidance while Mallinckrodt (MNK) said it does expect the new tax structure to have an immediate impact. BMO views yesterday's pullback in shares of Allergan, Mallinckrodt and Actavis (ACT) as an overreaction.
October 13, 2014
15:12 EDTACTActavis may see modest negative impact from Irish tax change, says BMO Capital
Subscribe for More Information
10:08 EDTHSICOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:27 EDTHSICHenry Schein upgraded to Buy from Neutral at ISI Group
Subscribe for More Information
06:18 EDTHSICHenry Schein upgraded to Buy from Neutral at ISI Group
Subscribe for More Information
October 10, 2014
10:20 EDTACTFidelity supports potential merger between Actavis and Allergan, Reuters reports
Subscribe for More Information
10:03 EDTLLYEli Lilly olaratumab granted orphan designation as soft tissue sarcoma treatment
Subscribe for More Information
10:01 EDTQOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:57 EDTQQuintiles upgraded at ISI Group
As previously reported, ISI Group upgraded Quintiles to Buy from Neutral. The firm sees further upside to shares driven by market product development growth, effective capital deployment, and an improving outlook for IHS. Price target is $61.
07:37 EDTACTActavis more likely partner than Valeant if Allergan merges, says UBS
Subscribe for More Information
07:16 EDTHSICAmerican Society of Plastic Surgeons to hold annual meeting
Annual Meeting of ASPS is being held in Chicago on October 10-14.
06:19 EDTQQuintiles upgraded to Buy from Neutral at ISI Group
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use